Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

3SBio CEO Jing Lou On Building An Integrated Biopharma Company In China: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Shenyang Sunshine Pharmaceutical Company Limited, now known as 3SBio, was incorporated in 1993 in Shenyang, China, and was the first Chinese biotech company to list on NASDAQ. The company develops and manufactures recombinant protein-based products, including erythropoietin stimulating agents such as the firm's flagship product EPIAO. 3SBio CEO and co-founder Jing Lou spoke recently with PharmAsia News' Shanghai bureau about building an integrated biopharmaceutical company in China, and the opportunities and challenges of competing in the global market.

You may also be interested in...



After Brazil Onto China? Amgen Unveils Emerging Market Strategy

The world's largest biotech company Amgen Inc. aims to triple sales from emerging markets in five years through potential acquisitions and licensing back rights to current products, the company said during an April 21 business review meeting. Amgen's recent purchase of privately held Bergamo of Brazil for roughly $215 million, and its reacquisition of Brazilian rights to certain Amgen products from Mantecorp, indicate more such deals are on the way, analysts say

After Brazil Onto China? Amgen Unveils Emerging Market Strategy

The world's largest biotech company Amgen Inc. aims to triple sales from emerging markets in five years through potential acquisitions and licensing back rights to current products, the company said during an April 21 business review meeting. Amgen's recent purchase of privately held Bergamo of Brazil for roughly $215 million, and its reacquisition of Brazilian rights to certain Amgen products from Mantecorp, indicate more such deals are on the way, analysts say

New EPO Products Set To Boost Future Revenue For 3SBio

SHANGHAI - 3SBio generated revenues from increased sales of its recombinant human erythropoietin products but saw its earnings slip, according to the unaudited financial results for the second quarter ended June 30

Related Content

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel